Description

Cartalax 20mg – Synthetic Tripeptide for Cartilage and Connective Tissue Research

Cartalax (also known as Ala-Glu-Asp, AED, or T-31) is a synthetic tripeptide composed of alanine, glutamic acid, and aspartic acid . Its amino acid sequence mirrors a segment of the alpha-1 chain of type XI collagen, suggesting potential interactions with extracellular matrix components . This peptide was developed by the St. Petersburg Institute of Bioregulation and Gerontology and has been investigated in Russian medical research, military rehabilitation, and anti-aging studies .

Unlike conventional compounds that primarily address inflammation or pain, Cartalax is designed to target chondrocytes—the cells responsible for cartilage maintenance and repair—at the level of gene expression . This tissue-specific mechanism positions Cartalax as a unique tool for cartilage homeostasis and regenerative research .

Key Research Applications

• Chondrocyte Function and Cartilage Repair – Investigated for its potential to modulate chondrocyte activity, support cellular proliferation, and reduce apoptosis in cartilage tissue .

• Extracellular Matrix (ECM) Synthesis – Studied for its effects on matrix metalloproteinases (MMPs) and collagen synthesis, particularly type II collagen and aggrecan production .

• Osteoarthritis and Joint Degeneration Research – Examined in animal models of osteoarthritis as a potential chondroprotective agent that may reduce cartilage degradation .

• Cellular Senescence and Aging Studies – May reduce the expression of senescence markers such as p16, p21, and p53 while upregulating SIRT6, a sirtuin linked to longevity and genomic stability .

• Anti-inflammatory and Immunomodulatory Research – Thought to suppress NF-κB expression and reduce pro-inflammatory cytokine activity, mitigating cartilage degradation .

Molecular and Technical Specifications

• Molecular Formula: C12H19N3O8

• Molecular Weight: ~333.29 g/mol

• Purity: ≥98% (HPLC)

• Dosage: 20mg per vial

• Form: Lyophilized powder

• Sequence: H-Ala-Glu-Asp-OH (AED)

• Synonyms: Cartalax; Ala-Glu-Asp; AED; T-31

• Storage: -20°C; protect from light

Research Background

Cartalax was initially developed for cartilage and connective tissue research as a tissue-specific bioregulator from the Khavinson peptide lineage . Studies have shown that the AED peptide can shift chondrocyte gene expression toward a more anabolic state, promoting healthy matrix synthesis over matrix degradation . In cell culture models, Cartalax has been observed to increase IGF-1 expression in aging human stem cells and promote collagen synthesis . The peptide has demonstrated efficacy in animal models of osteoarthritis and in oral administration with older OA patients in Russian studies .

Important Safety Notice

⚠️ FOR RESEARCH PURPOSES ONLY

This product is strictly intended for in-vitro research and laboratory use only. It is not approved for human consumption, therapeutic use, or clinical applications by any regulatory authority (e.g., FDA, EMA, MHRA) . Cartalax is not registered as a medicinal product in the UK, EU, or US . This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease .

This product is sold as a research chemical only. Not for human or veterinary therapeutic use.

Adipotide 5mg | Adipose-Targeting Research Peptide